Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review6,8-Bis(benzylthio)octanoic acid is a pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase (KGDH) inhibitor. Disrupts tumor cell mitochondrial metabolism, and increases mitochondrial reactive oxygen species (ROS) production in H460 lung carcinoma cells. Has no effect on KGDH activity in normal bronchial epithelial cells. Induces cell death of multiple tumor cell lines selectively over normal cells in vitro. Inhibits tumor growth of H460 and BxPC-3 tumor cell xenografts in mice.
M. Wt | 388.59 |
Formula | C22H28O2S2 |
Storage | Store at +4°C |
Purity | ≥99% (HPLC) |
CAS Number | 95809-78-2 |
PubChem ID | 24770514 |
InChI Key | ZYRLHJIMTROTBO-UHFFFAOYSA-N |
Smiles | OC(CCCCC(SCC2=CC=CC=C2)CCSCC1=CC=CC=C1)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 38.86 | 100 | |
ethanol | 38.86 | 100 |
The following data is based on the product molecular weight 388.59. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.57 mL | 12.87 mL | 25.73 mL |
5 mM | 0.51 mL | 2.57 mL | 5.15 mL |
10 mM | 0.26 mL | 1.29 mL | 2.57 mL |
50 mM | 0.05 mL | 0.26 mL | 0.51 mL |
References are publications that support the biological activity of the product.
Zachar et al (2011) Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J.Mol.Med. (Berl.) 89 1137 PMID: 21769686
Stuart et al (2014) A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2 4 PMID: 24612826
Egawa et al (2018) Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma. PLoS One 13 e0198940 PMID: 29879220
If you know of a relevant reference for 6,8-Bis(benzylthio)octanoic acid, please let us know.
Keywords: 6,8-Bis(benzylthio)octanoic acid, 6,8-Bis(benzylthio)octanoic acid supplier, 6,8-Bis(benzylthio)octanoic, acid, CPI613, Pyruvate, dehydrogenase, PDH, a-ketoglutarate, alpha, KGDH, inhibitors, inhibits, antitumor, active, in, vivo, xenografts, cell, death, Other, Dehydrogenases, 5348, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for 6,8-Bis(benzylthio)octanoic acid include:
Norbert et al (2020) Mitochondrial Ca2+ Signaling Is an Electrometabolic Switch to Fuel Phagosome Killing. Cell Rep 33 108411 PMID: 33238121
Do you know of a great paper that uses 6,8-Bis(benzylthio)octanoic acid from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review 6,8-Bis(benzylthio)octanoic acid and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.